
In antibody therapy, researchers create custom-made antibodies that bind to cells such as tumor cells, flagging them for destruction by the immune system. It’s a powerful technology — but for some types of cells, there’s nowhere to attach an antibody. Solu Therapeutics literally bridges this gap using proprietary molecules called Cytotoxicity Targeting Chimeras (CyTaCs) that attach to target cells on one end and antibodies on the other. The company’s first clinical candidate will target blood cancers.
In The Media
Explore Companies

Grove Biopharma
Putting protein-like drugs inside cells to fight cancer and neurodegeneration

Syntax Bio
Programming stem cells to differentiate into desired cell types, faster

Fable Therapeutics
Using state-of-the-art machine learning models to create custom-build protein drugs

Nilo Therapeutics
Mapping the brain-body axis to achieve proper immune balance